estech’s CEO, Dr Greg Roger, will be chairing a seminar in Perth August 12 for ICN. This seminar, covering Regulatory Issues and Commercialisation Essentials is a development from the two seminars held in Sydney and Melbourne in MAy and June this year as part of the Federal Government’s Advocate Program.
The CONVERGE Summit for Healthcare Innovation, held in Philadelphia July 15th to 16th has been opened to the world by webcasting. Increasingly the teachings of the world’s best and brightest is open to innovators in every corner of the world.
The annual BIO conference, this year held in San Diego, is the key meeting for the Biotechnology sector. Presentations by Hilary Clinton and Richard Branson were plenary highlights, with many other presentations on a variety of biotechnology areas being delivered through the four day meeting.
At a private reception at his home, H.E. Kim Beazley met with Dr Roger, who was able to discuss with the Ambassador and his advisors the import of his recent visit to the Walter Reed Hospital and the role of statistical methods and data mining in improving health care outcomes and reducing costly wastage of resources.
During a recent Washington visit, Dr Roger of Vestech was invited to meet with Cpt Eberhardt, senior trauma surgeon, to review the results of USU’s research into the results of reconstructive surgery in blast victims. The patients reviewed had each lost at least one limb in Afghanistan, primarily the result of blast injuries from IEDs.
In today’s Financial Review (7 July, 2014) Tim Dodd has written about the challenges in STEM teaching facing Australia (Why the next Zuckerberg won’t be Australian). Quoting Dr Nick Cerneaz, executive director of the Warren Centre for Advanced Engineering, the article has picked up on the future growth of our economy and how a poor STEM capability will inevitably crimp that growth.
At the recent International NanoMedicine conference Dr Greg Roger of Vestech Medical presented a paper entitled, “Achieving Success with your Innovation”, reflecting upon the lessons learned in 30 years of new product innovation.
Following his meetings at BIO Dr Roger was able to meet with the CEO of CONNECT, Greg McKee, to explore collaborations between this US-wide, Californian based innovation network and Australian firms wishing to export to the USA.
On a recent trip to New Zealand, Dr Roger met with David Budgett, Associate Professor, Technology Development Leader Auckland Bioengineering Institute (ABI) at the University of Auckland. Dr Roger was able to review the ABIs world-class research in tissue modeling and inducted power sources for medical devices.